Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma
Findings from the AQUILA study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1568 results
EMA Recommends Extension of Indications for Osimertinib
New indication concerns treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status
Findings from the EMBER-3 study
FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer
Evidence for efficacy is based on the results from the HERIZON-BTC-01 study
Lung Adenocarcinoma with Mucinous Histology
Clinicopathologic, genomic, immunophenotypic, transcriptional features, and treatment outcomes
Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult Maternal Cancer
Findings from the IDENTIFY study
Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL
Findings from the FELIX study
EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma
New indication concerns a combination with pemetrexed and platinum for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma
FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation
Evidence for efficacy is based on the results from the AUGMENT-101 study
Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC
Findings from the CheckMate 8HW study
Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL
Findings from the STARGLO study
Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with Low-Volume de Novo Metastatic Castration-Sensitive Prostate Cancer
Findings from the PEACE-1 study